Why Is UROGEN PHARMA LTD (URGN) Stock Moving Today?

Why URGN stock is up today

UroGen Pharma stock surged 16.31% to $46.43 in intraday trade on August 5, 2026, driven by a strong earnings report and positive guidance. The company reported second-quarter revenue of $72.5 million, exceeding estimates by $8.96 million, with ZUSDURI revenue alone reaching $50.4 million, up 73% quarter-over-quarter. The stock also benefited from a new patent extension for ZUSDURI, which now offers protection through 2044, reinforcing the company's long-term growth potential.

What Happened

UroGen posted a standout second quarter with ZUSDURI revenue jumping 73% to $50.4 million, supported by strong clinical data and expanded adoption. The company also provided updated 2026 operating expense guidance of $260 million to $270 million. A new U.S. patent for ZUSDURI, supported by the ENVISION and ATLAS trials, was granted a notice of allowance by the U.S. Patent and Trademark Office, extending its exclusivity until 2044. The stock’s sharp rise also followed a GAAP loss of $0.28 per share, in line with expectations, and a 52.9% year-to-date revenue increase.

What The Data Shows

The stock’s 16.31% gain came on heavy volume, though no specific volume figure is provided. The 52-week range is $15.86 to $43.93, meaning the current price of $46.43 exceeds its recent high. UroGen remains unprofitable with a trailing twelve-month EPS of -2.73 and a net margin of -94.8%. The company’s market cap is $1.9 billion, and it carries a beta of 1.57, indicating higher volatility than the broader market. In the past 90 days, insiders have sold a total of $1.2 million in shares, with the most recent filing on July 10.

What To Watch

UroGen has not announced an upcoming earnings date. Investors should monitor the breadth of analyst coverage and any further updates on ZUSDURI’s market performance and patent developments.